Oncology Medical News

Your Unread Messages

See All

Tracy Hampton, PhD

Clinical Trial Watch

Whole-Brain Radiation Affects Learning and Memory in Brain Cancer Patients

Roberta Buell, MBA
CMS Re-Validates Enrollment of Big Billers

Dorothy J. Schirf, MD

Technology Advances

Radiosurgery Trial Sparks Optimism for Early Lung Cancer

Sara Hartley

Cancer Science

Using Embryonic Stem Cells to Test Breast Cancer Genes

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy
Supportive Care in Cancer, 11/06/09

Gridelli C et al. – The addition of casopitant to ondansetron and dexamethasone in patients receiving HEC was significantly more effective in reducing the impact of nausea and vomiting on all daily life activities as assessed by the FLIE compared with ondansetron/dexamethasone dual therapy.

Methods

Multicenter, double-blind, randomized, placebo-controlled, add-on trial (N?=?810)
Patients randomized to intravenous (IV) ondansetron/dexamethasone alone (control) or in combination with either single 150-mg oral dose of casopitant or 3-day IV/oral casopitant
Quality of life assessed as impact of nausea and vomiting on daily life using Functional Living Index Emesis (FLIE) questionnaire
Patients completed FLIE questionnaire at baseline prior to receiving chemotherapy and after completion of first cycle of HEC

Results

Patients in single oral dose and 3-day IV/oral casopitant groups scored higher mean total FLIE scores than patients in control group , indicating that casopitant patients experienced less impact from nausea and vomiting on daily life
Overall absolute difference in proportion of patients reporting CINV with no impact on daily life between single oral casopitant group and control group was 13%
Difference between 3-day IV/oral casopitant group and control group was 14%

<< Previous
Statin-independent prognosis of patients with diffuse large...

Next >>
Phase I/II study on docetaxel, gemcitabine and prednisone in...